Patents by Inventor Craig A. Shoemaker

Craig A. Shoemaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8420072
    Abstract: Vibrio vulnificus can cause infections in aquaculture-raised fish and is considered an opportunistic human pathogen. We isolated V. vulnificus from diseased hybrid tilapia (Oreochromis niloticus X O. aureus) cultured in a North American water reuse aquaculture facility. We have characterized the isolate using biochemical and molecular methods, developed a disease infection model, and determined that formalin-inactivated whole-cell vaccine provides protection against V. vulnificus. The V. vulnificus isolate was determined to be biotype 1, 16S rRNA type B, vcg type C, and vvhA type 2. Fish vaccinated with the formalin-inactivated whole-cell vaccine responded to vaccination as measured by agglutinating antibody titer. In two separate trials, vaccinated tilapia exhibited relative percent survival of 73 and 60% following challenge with the homologous isolate. In additional trials, vaccinated tilapia exhibited survival values of up to 87.5% following challenge with a heterologous isolate.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: April 16, 2013
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Craig A. Shoemaker, Benjamin R. LaFentz
  • Publication number: 20120244190
    Abstract: Vibrio vulnificus can cause infections in aquaculture-raised fish and is considered an opportunistic human pathogen. We isolated V. vulnificus from diseased hybrid tilapia (Oreochromis niloticus X O. aureus) cultured in a North American water reuse aquaculture facility. We have characterized the isolate using biochemical and molecular methods, developed a disease infection model, and determined that formalin-inactivated whole-cell vaccine provides protection against V. vulnificus. The V. vulnificus isolate was determined to be biotype 1, 16S rRNA type B, vcg type C, and vvhA type 2. Fish vaccinated with the formalin-inactivated whole-cell vaccine responded to vaccination as measured by agglutinating antibody titer. In two separate trials, vaccinated tilapia exhibited relative percent survival of 73 and 60% following challenge with the homologous isolate. In additional trials, vaccinated tilapia exhibited survival values of up to 87.5% following challenge with a heterologous isolate.
    Type: Application
    Filed: March 24, 2011
    Publication date: September 27, 2012
    Inventors: Craig A. Shoemaker, Benjamin R. LaFentz
  • Patent number: 7988977
    Abstract: Safe and effective live vaccines against Aeromonas hydrophila of fish were created through the induction of rifampicin resistance in native Aeromonas hydrophila isolates; these including rifampicin-resistant mutants NRRL-B-50040 and NRRL-B-50041. Single immersion exposure of fish stimulated acquired immunity against virulent Aeromonas hydrophila infection.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: August 2, 2011
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Phillip H. Klesius, Craig A. Shoemaker, Joyce L. Evans
  • Publication number: 20100221286
    Abstract: Safe and effective live vaccines against Aeromonas hydrophila of fish were created through the induction of rifampicin resistance in native Aeromonas hydrophila isolates; these including rifampicin-resistant mutants NRRL-B-50040 and NRRL-B-50041. Single immersion exposure of fish stimulated acquired immunity against virulent Aeromonas hydrophila infection.
    Type: Application
    Filed: February 27, 2009
    Publication date: September 2, 2010
    Inventors: Phillip H. Klesius, Craig A. Shoemaker, Joyce L. Evans
  • Patent number: 7204993
    Abstract: A composition prepared from intact killed cells of isolated ?-hemolytic Streptococcus agalactiae and a concentrated extract of a culture of ?-hemolytic Streptococcus agalactiae, is effective for the protection of fish against infection by the same and other virulent strains Streptococcus agalactiae.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: April 17, 2007
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Joyce J. Evans, Phillip H. Klesius, Craig A. Shoemaker
  • Patent number: 7067122
    Abstract: A safe and effective live vaccine against Edwardsiella tarda in fish was created through the induction of rifampicin resistance in a native Edwardsiella tarda isolate. Single immersion exposure or injection of fish stimulated acquired immunity against virulent E. tarda infection.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: June 27, 2006
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Joyce J. Evans, Phillip H. Klesius, Craig A. Shoemaker
  • Patent number: 6991793
    Abstract: Safe and effective live vaccines against Flavobacterium columnare of fish were created through the induction of rifampicin resistance in a native Flavobacterium columnare isolate; these including rifampicin-resistant mutants NRRL B-30303 and B-30304. Single immersion exposure of fish stimulated acquired immunity against virulent F. columnare infection.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: January 31, 2006
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Craig A. Shoemaker, Phillip H. Klesius, Joyce J. Evans
  • Patent number: 6984388
    Abstract: A safe and effective live vaccine against Flavobacterium columnare of fish was created through the induction of an adhesion deficient isolate of Flavobacterium columnare using a ?-lactam antibiotic (ampicillin). Single immersion exposure of fish stimulated acquired immunity against virulent F. columnare infection.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: January 10, 2006
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Joel A. Bader, Craig A. Shoemaker, Phillip H. Klesius
  • Patent number: 6881412
    Abstract: Safe and effective live vaccines against Flavobacterium columnare of fish were created through the induction of rifampicin resistance in a native Flavobacterium columnare isolate; these including rifampicin-resistant mutants NRRL B-30303 and B-30304. Single immersion exposure of fish stimulated acquired immunity against virulent F. columnare infection.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: April 19, 2005
    Assignee: The United States of America as represented by the Secretary of the Agriculture
    Inventors: Craig A. Shoemaker, Phillip H. Klesius, Joyce J. Evans
  • Publication number: 20040234535
    Abstract: Safe and effective live vaccines against Flavobacterium columnare of fish were created through the induction of rifampicin resistance in a native Flavobacterium columnare isolate; these including rifampicin-resistant mutants NRRL B-30303 and B-30304. Single immersion exposure of fish stimulated acquired immunity against virulent F. columnare infection.
    Type: Application
    Filed: June 17, 2004
    Publication date: November 25, 2004
    Applicant: United States of America, as represented by the Secretary of Agriculture
    Inventors: Craig A. Shoemaker, Phillip H. Klesius, Joyce J. Evans
  • Patent number: 6379677
    Abstract: Safe and effective mono and polyvalent vaccines against Streptococcus iniae may be prepared from formalin-killed cells and concentrated extracellular products of Streptococcus iniae which include one or more of deposited strains NRRL B-30238 and NRRL B-30242. Intraperitoneal and intramuscular vaccination of tilapia show acquisition of effective immunity against homologous and heterologous isolates of S. iniae.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: April 30, 2002
    Assignee: The United States of America as represented by the Secretary of the Department of Agriculture
    Inventors: Phillip H. Klesius, Craig A. Shoemaker, Joyce J. Evans
  • Patent number: 6153202
    Abstract: Methods for the safe and effective live in ovo vaccination of eyed eggs of catfish against enteric septicemia of catfish (ESC) were created through the use of rifampicin resistant native E. ictaluri isolates; these including rifampicin-resistant strain ATCC 202058 of Edwardsiella ictaluri originally isolated from the walking catfish Clarius batrachus from Thailand. Single immersion exposure of eyed eggs of catfish stimulated strong acquired immunity against many isolates of E. ictaluri without the need for booster immunization.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: November 28, 2000
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Phillip H. Klesius, Craig A. Shoemaker, Joyce J. Evans
  • Patent number: 6019981
    Abstract: Safe and effective live vaccines against enteric septicemia of catfish (ESC) were created through the induction of rifampicin resistance in native E. ictaluri isolates; these including rifampicin-resistant strain (RE-33) of Edwardsiella ictaluri originally isolated from the walking catfish Clarius batrachus from Thailand. Single immersion exposure of catfish fry stimulated strong acquired immunity against many isolates of E. ictaluri without the need for booster immunization.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: February 1, 2000
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Phillip H. Klesius, Craig A. Shoemaker
  • Patent number: 5543330
    Abstract: An improved method for diagnosing myofibrogranuloma (MFG) in walleye without harming the fish is described. Blood samples are drawn from walleye and creatinine and calcium levels are then determined along with the sex and length of the fish. These data are then analyzed and compared to data from healthy walleye using discriminant analysis. The process is effective for identifying approximately 88% of MFG-positive walleye.
    Type: Grant
    Filed: September 22, 1995
    Date of Patent: August 6, 1996
    Assignee: Center for Innovation & Business Development Foundation
    Inventors: Harry L. Holloway, Jr., Craig A. Shoemaker